• Corpus ID: 78230601

PERFLENAPENT EMULSION : ULTRASOUND CONTRAST MEDIA

@article{Worah1997PERFLENAPENTE,
  title={PERFLENAPENT EMULSION : ULTRASOUND CONTRAST MEDIA},
  author={Dilip Worah and Dean R. Kessler and Adrienne R Meuter and Meichu Huang and Jean-Michel Correas and Steven Carl Quay},
  journal={Drugs of The Future},
  year={1997},
  volume={22},
  pages={378-385}
}
No Paper Link Available
10 Citations

10 Citations

Acoustic droplet vaporization and propulsion of perfluorocarbon-loaded microbullets for targeted tissue penetration and deformation.
Acoustic droplet vaporization of perfluorocarbon-loaded microbullets triggered by an ultrasound pulse provides the necessary force to penetrate, cleave, and deform cellular tissue for potential…
Fluorous micro- and nanophases with a biomedical perspective
Chapter 23 – Fluorocarbon emulsions—Designing an efficient shuttle service for the respiratory gases—The so-called ‘Blood Substitutes’
Carbohydrate- and related polyol-derived fluorosurfactants: an update.
Comparison of the efficacy of two air-based contrast agents in dogs.
Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging.
TLDR
SonoVue appeared to be safe and well tolerated in healthy subjects and rapidly removed from the blood by the pulmonary route, and the route of SF6 elimination was by means of the lungs in the expired air.
Fluorocarbons and Fluorosurfactants for In Vivo Oxygen Transport (Blood Substitutes), Imaging, and Drug Delivery
The development of biomaterials to treat, repair, or reconstruct the human body is an increasingly important component of materials research. Collaboration between materials researchers and their…
In vivo kinetics of microbubbles of SH U 508 A (Levovist): comparison with indocyanine green in rabbits.
Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution.
Perflenapent emulsion (echogen®): A new long‐acting phase‐shift agent for contrast echocardiography
TLDR
Perflenapent emulsion should permit the use of echocardiography to visualize and localize myocardial perfusion deficits at rest by producing a negative contrast effect, allowing physicians to diagnose coronary artery disease, including the extent of a lesion's impact on the perfusion of the myocardium, in a timely and cost‐efficient manner.